Bryleos
Bryleos is developing BRY101, a metabolic modulator that increases intracellular NAD levels to target mitochondrial dysfunction, neuroinflammation, and oxidative stress associated with neurodegenerative and neuromuscular disorders. This multi-pathway approach diverges from traditional single-target drug development, aiming to improve patient outcomes in complex neurological conditions.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$5.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Bryleos is developing BRY101, a metabolic modulator that increases intracellular NAD levels to target mitochondrial dysfunction, neuroinflammation, and oxidative stress associated with neurodegenerative and neuromuscular disorders. This multi-pathway approach diverges from traditional single-target drug development, aiming to improve patient outcomes in complex neurological conditions.